Over 52 weeks, the Achieve-3 study compared two doses of Foundayo with approved oral semaglutide doses in 1,698 people with type 2 diabetes who were not adequately controlled on metformin.
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.